Prime Medicine (PRME) Competitors $3.79 +0.11 (+2.99%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.77 -0.02 (-0.53%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. IDYA, TWST, GLPG, AGIO, BEAM, VCEL, IRON, HRMY, MESO, and CNTAShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include IDEAYA Biosciences (IDYA), Twist Bioscience (TWST), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Beam Therapeutics (BEAM), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors IDEAYA Biosciences Twist Bioscience Galapagos Agios Pharmaceuticals Beam Therapeutics Vericel Disc Medicine Harmony Biosciences Mesoblast Centessa Pharmaceuticals IDEAYA Biosciences (NASDAQ:IDYA) and Prime Medicine (NYSE:PRME) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Which has more volatility & risk, IDYA or PRME? IDEAYA Biosciences has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Which has preferable valuation & earnings, IDYA or PRME? Prime Medicine has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M289.21-$274.48M-$3.79-6.09Prime Medicine$3.85M132.54-$198.13M-$1.61-2.35 Does the media favor IDYA or PRME? In the previous week, IDEAYA Biosciences had 13 more articles in the media than Prime Medicine. MarketBeat recorded 21 mentions for IDEAYA Biosciences and 8 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.45 beat IDEAYA Biosciences' score of 0.41 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 5 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is IDYA or PRME more profitable? IDEAYA Biosciences' return on equity of -31.42% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -31.42% -29.45% Prime Medicine N/A -107.87%-74.97% Do institutionals and insiders hold more shares of IDYA or PRME? 98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 2.5% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 22.7% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate IDYA or PRME? IDEAYA Biosciences currently has a consensus target price of $48.09, suggesting a potential upside of 108.19%. Prime Medicine has a consensus target price of $8.92, suggesting a potential upside of 135.27%. Given Prime Medicine's higher possible upside, analysts plainly believe Prime Medicine is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.77Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryIDEAYA Biosciences and Prime Medicine tied by winning 8 of the 16 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$509.74M$289.09M$5.51B$20.74BDividend YieldN/AN/A4.60%3.66%P/E Ratio-1.85N/A30.0128.05Price / Sales132.54462.25450.7256.18Price / CashN/A22.4436.7723.05Price / Book2.778.908.184.33Net Income-$198.13M-$115.81M$3.26B$994.32M7 Day Performance-6.19%-2.68%6.13%1.97%1 Month Performance-19.19%-8.15%0.07%-1.60%1 Year Performance-9.65%-4.26%36.31%14.39% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.6483 of 5 stars$3.79+3.0%$8.92+135.3%-9.7%$509.74M$3.85M-1.85234News CoverageAnalyst ForecastIDYAIDEAYA Biosciences4.0787 of 5 stars$25.02+2.1%$48.09+92.2%-39.0%$2.19B$7M-6.9780News CoverageEarnings ReportAnalyst RevisionTWSTTwist Bioscience3.4556 of 5 stars$36.53+1.5%$50.40+38.0%-41.7%$2.19B$312.97M-11.24990Trending NewsEarnings ReportAnalyst RevisionGLPGGalapagos0.2556 of 5 stars$32.79+0.4%$25.33-22.7%+31.2%$2.16B$275.61M0.001,310News CoverageAnalyst ForecastAGIOAgios Pharmaceuticals4.152 of 5 stars$37.20-7.0%$57.33+54.1%-18.2%$2.15B$36.50M3.31390BEAMBeam Therapeutics2.5648 of 5 stars$20.83-4.1%$48.75+134.0%-28.0%$2.09B$63.52M-4.52510Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionVCELVericel2.0648 of 5 stars$41.45+3.3%$61.14+47.5%-20.5%$2.09B$237.22M1,382.13300IRONDisc Medicine3.3654 of 5 stars$59.48-1.9%$95.73+60.9%+34.7%$2.06BN/A-15.1730News CoverageEarnings ReportHRMYHarmony Biosciences4.629 of 5 stars$35.76-4.7%$51.00+42.6%+1.0%$2.05B$714.73M13.65200Earnings ReportAnalyst DowngradeAnalyst RevisionMESOMesoblast1.4213 of 5 stars$15.93-2.6%$18.00+13.0%+143.6%$2.04B$5.67M0.0080News CoveragePositive NewsAnalyst UpgradeCNTACentessa Pharmaceuticals3.1 of 5 stars$15.20-1.4%$28.10+84.9%+54.2%$2.03B$6.85M-8.40200Positive NewsUpcoming Earnings Related Companies and Tools Related Companies IDEAYA Biosciences Alternatives Twist Bioscience Alternatives Galapagos Alternatives Agios Pharmaceuticals Alternatives Beam Therapeutics Alternatives Vericel Alternatives Disc Medicine Alternatives Harmony Biosciences Alternatives Mesoblast Alternatives Centessa Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts